Journal
LEUKEMIA & LYMPHOMA
Volume 46, Issue 6, Pages 935-939Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428190500054426
Keywords
human; cancer vaccines; tumor immunity; chronic lymphocytic leukemia; costimulatory molecules; toll-like receptors
Categories
Ask authors/readers for more resources
The identification of clinically relevant, active immunomodulatory agents is important for developing immunotherapeutic approaches to chronic lymphocytic leukemia ( CLL) and other B-cell lymphomas that are not curable with conventional chemotherapy. In this investigation, the imidazoquinoline Toll-like receptor ( TLR)-7/8 agonist, imiquimod, was found to mediate the clearance of a lymphomatous skin lesion in a CLL patient. Imidazoquinolines also activated TLR-7/8 signaling pathways, resulting in increased expression of costimulatory molecules on circulating tumor cells. These observations extend the therapeutic spectrum of imiquimod to cutaneous B-cell lymphomas and suggest the use of TLR-7/8 agonists in CLL immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available